UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

Journal of clinical oncology, 2009-07, Vol.27 (20), p.3312-3318

2009

Volltextzugriff (PDF)

A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma

Nature communications, 2019-03, Vol.10 (1), p.1152-13, Article 1152

2019

Volltextzugriff (PDF)

Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis

European urology, 2018-11, Vol.74 (5), p.611-620

2018

Volltextzugriff (PDF)

Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma

Clinical cancer research, 2004-09, Vol.10 (18), p.6388S-6392s

2004

Volltextzugriff (PDF)

The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer

Health technology assessment (Winchester, England), 2016-05, Vol.20 (40), p.1-146

2016

Volltextzugriff (PDF)

Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma

Genes chromosomes & cancer, 2014-01, Vol.53 (1), p.38-51

2014

Volltextzugriff (PDF)

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer

EMBO molecular medicine, 2018-06, Vol.10 (6), p.1-n/a

2018

Volltextzugriff (PDF)

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2505-2512

2006

Volltextzugriff (PDF)

Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK

BMC cancer, 2020-07, Vol.20 (1), p.670-670, Article 670

2020

Volltextzugriff (PDF)

Medical treatment of renal cancer: new horizons

British journal of cancer, 2016-08, Vol.115 (5), p.505-516

2016

Volltextzugriff (PDF)

ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease

European urology, 2011-10, Vol.60 (4), p.684-690

2011

Volltextzugriff (PDF)

The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort

BMC medicine, 2019-10, Vol.17 (1), p.182-182, Article 182

2019

Volltextzugriff (PDF)

Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer

Journal of clinical oncology, 2006-12, Vol.24 (35), p.5584-5592

2006

Volltextzugriff (PDF)

Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT

Health technology assessment (Winchester, England), 2024-08, Vol.28 (45), p.1-171

2024

Volltextzugriff (PDF)

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial

The lancet oncology, 2012-10, Vol.13 (10), p.1055-1062

2012

Volltextzugriff (PDF)

Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose

Journal of clinical oncology, 2007-10, Vol.25 (29), p.4542-4549

2007

Volltextzugriff (PDF)

A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-09, Vol.29 (26), p.3567-3573

2011

Volltextzugriff (PDF)

VHL, the story of a tumour suppressor gene

Nature reviews. Cancer, 2015-01, Vol.15 (1), p.55-64

2015

Volltextzugriff (PDF)

Alterations in VHL as potential biomarkers in renal-cell carcinoma

Nature reviews. Clinical oncology, 2010-05, Vol.7 (5), p.277-288

2010

Volltextzugriff (PDF)

Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?

Expert opinion on investigational drugs, 2021-12, Vol.30 (12), p.1221-1229

2021

Volltextzugriff (PDF)

Targeting Multiple Kinase Pathways: A Change In Paradigm

Clinical cancer research, 2010-04, Vol.16 (7), p.1973-1978

2010

Volltextzugriff (PDF)

1 – 25 von 207

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(195)
Mit Volltextzugriff
(185)

Publikationsform

Artikel
(201)
Buchkapitel
(6)

Sprache

Englisch
(203)
Deutsch
(4)

Erscheinungsjahr

n.n

Thema

Science & Technology
(131)
Life Sciences & Biomedicine
(127)
Humans
(117)
Oncology
(87)
Female
(52)
Biological And Medical Sciences
(51)
Male
(50)
Medical Sciences
(50)
Carcinoma, Renal Cell - Drug Therapy
(47)
Kidney Neoplasms - Drug Therapy
(45)
Middle Aged
(41)
Tumors
(37)
Aged
(35)
Antineoplastic Agents - Therapeutic Use
(34)
Kidney Neoplasms - Pathology
(31)
Renal Cell Carcinoma
(28)
Adult
(26)
Carcinoma, Renal Cell - Pathology
(26)
Metastasis
(23)
Kidney Cancer
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma

Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis

Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma

The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer

Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK

Medical treatment of renal cancer: new horizons

ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease

The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort

Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer

Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial

Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose

The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol

A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non–Small-Cell Lung Cancer

VHL, the story of a tumour suppressor gene

Alterations in VHL as potential biomarkers in renal-cell carcinoma

Combination therapies in clinical trials for renal cell carcinoma: how could they impact future treatments?

Targeting Multiple Kinase Pathways: A Change In Paradigm

Suchergebnisse filtern